RUA Life Sciences PLC - Glasgow-based medical technology holding company - Expects to report year-on-year revenue growth of 34% for the year ended on March 31, with revenue of £2.2 million produced from Contract Manufacture, £1.6 million, and Biomaterials, £554,000. Expects pretax loss to be similar to last year at around £2.3 million to £2.4 million. For financial 2022, revenue was £1.6 million and pretax loss was £2.4 million.

Chair Bill Brown says: ‘RUA has a portfolio of four businesses, all of which have made good progress during the period. The mature businesses are growing revenue and generating attractive net margins and the development business segments of Vascular and Structural Heart have made good regulatory and technological progress respectively on relatively low levels of investment.’

Current stock price: 43.00 pence each, up 7.5% on Wednesday midday in London

12-month change: down 1.2%

Copyright 2023 Alliance News Ltd. All Rights Reserved.